Aldeyra Therapeutics Inc (STU:137)
€ 4.654 -0.037 (-0.79%) Market Cap: 276.29 Mil Enterprise Value: 184.32 Mil PE Ratio: 0 PB Ratio: 3.43 GF Score: 39/100

Aldeyra Therapeutics, Inc. - Special Call Transcript

Feb 28, 2019 / 12:30PM GMT
Release Date Price: €6.74 (+2.12%)
Todd C. Brady
Aldeyra Therapeutics, Inc. - CEO, President & Director

Good morning. Thank you all for coming. It is gratifying to see so many of you here and to see how this conference has -- this meeting has grown over the years. We're very appreciative of all our buy-side and sell-side colleagues. I can tell you for certain that those of us at Aldeyra are working very hard on your behalf every day.

I read something about Aldeyra recently that I want to affirm. It is not our intent to build a small company. It is not our intent to launch only one drug. It is not our intent to develop only one molecule or only one mechanism of action. However, our process for growth and adding to our pipeline is deliberate. It is systematic. It is a product of a well-defined and, I think, thoughtful and purposeful rubric. And today, our Chief Commercial Officer, Dave McMullin, will talk to you about how we think about adding to our pipeline and growing our R&D engine.

Our latest acquisition of Helio Vision fits perfectly within that rubric, and we're so thrilled to have Dr. Dean Eliott from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot